- Newsletter
- July 2025
- 75 Pages
Global
€4210EUR$4,750USD£3,660GBP
- Report
- January 2025
- 492 Pages
Global
From €8859EUR$9,995USD£7,702GBP
- Report
- January 2025
- 40 Pages
Global
From €4427EUR$4,995USD£3,849GBP
- Report
- March 2025
- 174 Pages
United States
From €7087EUR$7,995USD£6,161GBP
- Report
- December 2023
- 142 Pages
Global
From €3156EUR$3,560USD£2,743GBP
€3944EUR$4,450USD£3,429GBP
- Report
- May 2024
- 388 Pages
United States
From €7087EUR$7,995USD£6,161GBP
- Report
- August 2023
- 292 Pages
Europe
From €7973EUR$8,995USD£6,931GBP
- Report
- March 2023
- 251 Pages
United States
From €7087EUR$7,995USD£6,161GBP
- Report
- December 2022
- 105 Pages
Global
From €4427EUR$4,995USD£3,849GBP
- Report
- December 2022
- 421 Pages
Global
From €8859EUR$9,995USD£7,702GBP
- Report
- December 2022
- 31 Pages
Global
From €4427EUR$4,995USD£3,849GBP
The INFUSE Bone Graft is a type of orthopedic device used to promote bone growth and healing. It is a biologic product that is made from recombinant human bone morphogenetic protein-2 (rhBMP-2) and is used to treat a variety of orthopedic conditions, including spinal fusion, trauma, and revision surgery. The INFUSE Bone Graft is designed to be used in combination with other orthopedic devices, such as cages, screws, and plates, to provide a more complete solution for the patient.
The INFUSE Bone Graft market is a rapidly growing segment of the orthopedic device industry. It is a highly competitive market, with a number of companies offering products that are designed to meet the needs of surgeons and patients. Companies in the market include Medtronic, Stryker, Zimmer Biomet, DePuy Synthes, and Smith & Nephew. Show Less Read more